Harrow (HROW) Competitors $35.89 -0.25 (-0.69%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$36.60 +0.70 (+1.96%) As of 07/18/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. CRSP, ADMA, RYTM, PCVX, AKRO, KRYS, CYTK, ZLAB, PTCT, and RAREShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), Rhythm Pharmaceuticals (RYTM), Vaxcyte (PCVX), Akero Therapeutics (AKRO), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), PTC Therapeutics (PTCT), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. Harrow vs. Its Competitors CRISPR Therapeutics ADMA Biologics Rhythm Pharmaceuticals Vaxcyte Akero Therapeutics Krystal Biotech Cytokinetics Zai Lab PTC Therapeutics Ultragenyx Pharmaceutical Harrow (NASDAQ:HROW) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do analysts prefer HROW or CRSP? Harrow presently has a consensus target price of $63.83, suggesting a potential upside of 77.86%. CRISPR Therapeutics has a consensus target price of $71.75, suggesting a potential upside of 10.16%. Given Harrow's stronger consensus rating and higher possible upside, analysts clearly believe Harrow is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53 Is HROW or CRSP more profitable? Harrow has a net margin of -10.19% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-10.19% -25.01% -4.27% CRISPR Therapeutics -1,023.64%-20.08%-17.13% Which has more volatility & risk, HROW or CRSP? Harrow has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Does the media favor HROW or CRSP? In the previous week, Harrow had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Harrow and 18 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 1.01 beat Harrow's score of 0.43 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in HROW or CRSP? 72.8% of Harrow shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 15.2% of Harrow shares are held by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, HROW or CRSP? Harrow has higher revenue and earnings than CRISPR Therapeutics. Harrow is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M6.60-$17.48M-$0.56-64.09CRISPR Therapeutics$37.31M150.75-$366.25M-$4.52-14.41 SummaryHarrow beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32B$2.44B$5.53B$9.42BDividend YieldN/A1.80%3.76%4.04%P/E Ratio-64.099.0228.2619.78Price / Sales6.60561.07416.1888.84Price / Cash262.47161.4735.8558.18Price / Book18.415.008.115.65Net Income-$17.48M$30.99M$3.25B$257.97M7 Day Performance2.75%1.69%1.63%3.74%1 Month Performance17.06%10.07%7.62%11.95%1 Year Performance43.50%0.90%32.74%19.22% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.4514 of 5 stars$35.89-0.7%$63.83+77.9%+43.5%$1.32B$199.61M-64.09180Trending NewsAnalyst RevisionCRSPCRISPR Therapeutics2.9151 of 5 stars$51.19-1.9%$71.75+40.2%+19.4%$4.42B$37.31M-11.33460Positive NewsInsider TradeAnalyst RevisionGap UpADMAADMA Biologics3.855 of 5 stars$17.88-2.2%$27.67+54.7%+25.2%$4.27B$426.45M21.04530Positive NewsRYTMRhythm Pharmaceuticals3.2173 of 5 stars$66.39+0.9%$78.07+17.6%+79.9%$4.22B$130.13M-23.63140Analyst ForecastAnalyst RevisionPCVXVaxcyte1.8159 of 5 stars$32.00-3.8%$136.50+326.6%-55.6%$4.13BN/A-8.02160News CoveragePositive NewsAKROAkero Therapeutics3.7714 of 5 stars$51.52-0.5%$82.50+60.1%+94.6%$4.11BN/A-26.4230Insider TradeKRYSKrystal Biotech4.5324 of 5 stars$139.74-2.3%$211.13+51.1%-27.6%$4.04B$290.52M33.59210News CoverageInsider TradeAnalyst RevisionCYTKCytokinetics4.0857 of 5 stars$33.36-3.8%$70.92+112.6%-34.0%$3.98B$19.22M-6.31250News CoverageInsider TradeZLABZai Lab3.3678 of 5 stars$35.48-2.5%$54.28+53.0%+79.9%$3.94B$398.99M-14.251,869Positive NewsPTCTPTC Therapeutics4.332 of 5 stars$47.98-2.2%$65.00+35.5%+46.0%$3.80B$806.78M7.371,410News CoverageInsider TradeAnalyst RevisionRAREUltragenyx Pharmaceutical4.361 of 5 stars$39.61-0.8%$87.00+119.6%-38.2%$3.74B$560.23M-6.741,294Trending NewsAnalyst RevisionGap Down Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives ADMA Biologics Alternatives Rhythm Pharmaceuticals Alternatives Vaxcyte Alternatives Akero Therapeutics Alternatives Krystal Biotech Alternatives Cytokinetics Alternatives Zai Lab Alternatives PTC Therapeutics Alternatives Ultragenyx Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HROW Stock Alerts